Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00211198 · ClinicalTrials.gov registry record · Phase 4

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

A Phase 4 study of Lymphoma, T-Cell, Cutaneous, sponsored by Eisai.

Completed
Registry status
Phase 4
Development phase
60
Enrollment target
9
Study locations

NCT00211198 is a Phase 4 study of Lymphoma, T-Cell, Cutaneous that has completed, run by Eisai. The registered enrollment target is 60 participants, below the 206-participant average among 4 other Lymphoma, T-Cell, Cutaneous trials with a reported enrollment target (71% lower). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00211198, a Phase 4 study of Lymphoma, T-Cell, Cutaneous, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 4
Development phase
60 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this research study is to evaluate how effective ONTAK is in the treatment of cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein called CD25 on the cancer cells makes a difference in how the body responds to the treatment. The hypothesis is that there is no difference in response rate for patients whose tumor cells are CD25 positive or negative.

Conditions Studied

Lymphoma, T-Cell, Cutaneous

Interventions

  • DRUG ONTAK (denileukin difitox, DAB389IL-2)

Study Locations (9)

Ohio

  • University Hospitals of Cleveland - Cleveland
  • Ohio State University - Columbus

California

  • City of Hope National Medical Center - Duarte

Connecticut

  • Yale University School of Medicine - New Haven

Iowa

  • The University of Iowa - Iowa City

Massachusetts

  • New England Medical Center - Boston

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Tennessee

  • Vanderbilt University - Nashville

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2001-05
Est. Completion 2006-01
Phase Phase 4

Sponsor

Eisai

287 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00211198

The ClinicalTrials.gov registry entry for NCT00211198 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 4 other Lymphoma, T-Cell, Cutaneous trials with a reported enrollment target (71% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma, T-Cell, Cutaneous appearing as the primary indexed condition, and to 1 intervention - of which ONTAK (denileukin difitox, DAB389IL-2) is the first listed.

NCT00211198 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Ohio, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00211198 about?

NCT00211198 is a clinical study titled "Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)". The purpose of this research study is to evaluate how effective ONTAK is in the treatment of cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein called CD25 on the cancer cells makes a difference in how the body responds to the treatment. The hypothesis is that ...

What is the current status of trial NCT00211198?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2001-05. Estimated completion is 2006-01.

What conditions does trial NCT00211198 study?

This clinical trial studies the following conditions: Lymphoma, T-Cell, Cutaneous.

What interventions are being tested in trial NCT00211198?

The interventions under investigation include: ONTAK (denileukin difitox, DAB389IL-2) (DRUG).

Who is sponsoring clinical trial NCT00211198?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00211198 being conducted?

This trial has 9 study locations across California, Connecticut, Iowa, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma, T-Cell, Cutaneous

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma, T-Cell, Cutaneous

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.